Biblio

Filters: First Letter Of Title is J [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

J

Yuan, Y., Lu, X., Chen, X., Shao, H., and Huang, S. (2013). Jagged1 contributes to the drug resistance of Jurkat cells in contact with human umbilical cord-derived mesenchymal stem cells.Oncol Lett6, 1000-1006.

Cahill, E.F., Tobin, L.M., Carty, F., Mahon, B.P., and English, K. (2015). Jagged-1 is required for the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells.Stem Cell Res Ther6, 19.

Warsch, W., Walz, C., and Sexl, V. (2013). JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.Blood.

Debeurme, F., Lacout, C., Moratal, C., Bagley, R.G., Vainchenker, W., Adrian, F., and Villeval, J.-L. (2015). JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.J Cell Mol Med.

Wang, X., Ye, F., Tripodi, J., Hu, C.Siang, Qiu, J., Najfeld, V., Novak, J., Li, Y., Rampal, R., and Hoffman, R. (2014). JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.Blood.

Langabeer, S.E., and Haslam, K. (2016). The JAK2 V617F mutation and thrombocytopenia.Hematol Oncol Stem Cell Ther.

Kong, X., Gong, Z., Zhang, L., Sun, X., Ou, Z., Xu, B., Huang, J., Long, D., He, X., Lin, X., et al. (2019). JAK2/STAT3 signaling mediates IL-6-inhibited neurogenesis of neural stem cells through DNA demethylation/methylation.Brain Behav Immun.

Vu, T., Austin, R., Kuhn, C.Paine, Bruedigam, C., Song, A., Guignes, S., Jacquelin, S., Ramshaw, H.S., Hill, G.R., Lopez, A.F., et al. (2015). Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.Haematologica.

Zhang, Y., Lin, C.Hua Sarah, Kaushansky, K., and Zhan, H. (2018). JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice through Thrombopoietin/MPL signaling.Stem Cells.

Li, J., Kent, D.G., Godfrey, A.L., Manning, H., Nangalia, J., Aziz, A., Chen, E., Saeb-Parsy, K., Fink, J., Sneade, R., et al. (2014). JAK2V617F-homozygosity drives a phenotypic switch between myeloproliferative neoplasms in a murine model, but is insufficient to sustain clonal expansion.Blood.

Sayoc-Becerra, A., Krishnan, M., Fan, S., Jimenez, J., Hernandez, R., Gibson, K., Preciado, R., Butt, G., and McCole, D.F. (2019). The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction.Inflamm Bowel Dis.

Forbes, L.R., Vogel, T.P., Cooper, M.A., Castro-Wagner, J., Schussler, E., Weinacht, K.G., Plant, A.S., Su, H.C., Allenspach, E.J., Slatter, M., et al. (2018). Jakinibs for the Treatment of Immunodysregulation in Patients with Gain of Function STAT1 or STAT3 Mutations.J Allergy Clin Immunol.

Ojha, R., Singh, S.K., and Bhattacharyya, S. (2016). JAK-mediated Autophagy Regulates Stemness and Cell Survival in Cisplatin Resistant Bladder Cancer Cells.Biochim Biophys Acta.

Staerk, J., and Constantinescu, S.N. (2012). The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.Jakstat1, 184-190.

Mohri, T., Iwakura, T., Nakayama, H., and Fujio, Y. (2012). JAK-STAT signaling in cardiomyogenesis of cardiac stem cells.Jakstat1, 125-130.

Stine, R.R., and Matunis, E.L. (2013). JAK-STAT Signaling in Stem Cells.Adv Exp Med Biol786, 247-67.

Bausek, N. (2013). JAK-STAT signaling in stem cells and their niches in Drosophila.Jakstat2, e25686.

W Y Lau, W., Hannah, R., Green, A.R., and Göttgens, B. (2015). The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients.Blood125, 1679-81.

Dolatabadi, S., Jonasson, E., Lindén, M., Fereydouni, B., Bäcksten, K., Nilsson, M., Martner, A., Forootan, A., Fagman, H., Landberg, G., et al. (2019). JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma.Int J Cancer.

Tang, Y., and Tian, X.Cindy (2013). JAK-STAT3 and somatic cell reprogramming.Jakstat2, e24935.

Sawai, T., Hatta, T., and Fujita, M. (2019). Japan Significantly Relaxes Its Human-Animal Chimeric Embryo Research Regulations.Cell Stem Cell24, 513-514.

Kuo, Y.-T., Liu, Y.-L., Adebayo, B.Oluwaseun, Shih, P.-H., Lee, W.-H., Wang, L.-S., Liao, Y.-F., Hsu, W.-M., Yeh, C.-T., and Lin, C.-M. (2015). JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.Plos One10, e0125343.

Yamamoto, S., Wu, Z., Russnes, H.G., Takagi, S., Peluffo, G., Vaske, C., Zhao, X., Vollan, H.Kristian M., Maruyama, R., Ekram, M.B., et al. (2014). JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer.Cancer Cell25, 762-777.

Celik, H., Koh, W.Kyun, Kramer, A.C., Ostrander, E.L., Mallaney, C., Fisher, D.A.C., Xiang, J., Wilson, W.C., Martens, A., Kothari, A., et al. (2018). JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.Cancer Cell34, 741-756.e8.

Lei, X., Xu, J.-F., Chang, R.-M., Fang, F., Zuo, C.-H., and Yang, L.-Y. (2016). JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.Oncotarget.

Pages